We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) to Report Q2 Earnings: Will it Disappoint?
Read MoreHide Full Article
Danaher Corp. (DHR - Free Report) is set to report second-quarter 2017 earnings results before the opening bell on Jul 20.
The company hasn't missed estimates in the trailing sixteen quarters, which is an impressive feat. Last quarter, it posted a positive earnings surprise of 1.2%. The stock boasts an average positive surprise of 5.7% over the past four quarters.
Let's see how things are shaping up for this announcement.
Factors to Consider
In the past few quarters, Danaher has faced stunted revenue growth in its dental segment, mainly attributable to weakness in higher-margin traditional consumables business. We believe the weakness will continue to mar the second-quarter results as well. Moreover, unfavourable product mix and incremental costs associated with various new product developments, particularly in the dental segment, are expected to hurt the margin performance for the soon-to-be-reported quarter.
This apart, sluggishness in some of Danaher’s key end markets, including Latin America and some European regions, are likely to impact growth. A significant portion of its revenues is derived from regions outside the U.S., which makes it vulnerable to currency fluctuations. Over the past few quarters, Danaher has been suffering from strengthening of both the U.S. dollar and the Japanese yen versus other currencies.
Also, the company has been witnessing relatively smaller organic growth over the past few quarters. We believe Danaher's Life Science portfolio lacks a significant upstream product offering, which has been restricting growth. A decelerating organic growth is likely to affect the company’s overall top-line performance for the second quarter.
Despite these negatives, Danaher’s acquired businesses, namely Pall and Cepheid, are expected to act as key growth drivers for the quarter to be reported. Also, the company’s robust operating culture, DBS, is likely to act as a catalyst. Historically, DBS has contributed to meaningful core revenue growth, adjusted earnings per share improvement and cash flow generation.
Furthermore, positive industry trends like new regulations from the Chinese Food and Drug Administration are expected to act as tailwinds, fueling top-line increase for the second quarter. Also, market traction of the recently launched products, including SMARTmatic handpiece campaign, KaVo OP 3D Pro panoramic X-Ray imaging system and CM130 coring monitoring system, are expected to stoke growth.
Earnings Whispers
Our proven model does not conclusively show that Danaher will beat earnings estimates in this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Earnings ESP for the company is currently 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 97 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Danaher has a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
3M Company (MMM - Free Report) has an Earnings ESP of +1.16% and holds a Zacks Rank #2. The company will release second-quarter 2017 earnings on Jul 25.
United Technologies Corporation has an Earnings ESP of +2.26% and carries a Zacks Rank #3. The company will report second-quarter 2017 results on Jul 25.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Danaher (DHR) to Report Q2 Earnings: Will it Disappoint?
Danaher Corp. (DHR - Free Report) is set to report second-quarter 2017 earnings results before the opening bell on Jul 20.
The company hasn't missed estimates in the trailing sixteen quarters, which is an impressive feat. Last quarter, it posted a positive earnings surprise of 1.2%. The stock boasts an average positive surprise of 5.7% over the past four quarters.
Let's see how things are shaping up for this announcement.
Factors to Consider
In the past few quarters, Danaher has faced stunted revenue growth in its dental segment, mainly attributable to weakness in higher-margin traditional consumables business. We believe the weakness will continue to mar the second-quarter results as well. Moreover, unfavourable product mix and incremental costs associated with various new product developments, particularly in the dental segment, are expected to hurt the margin performance for the soon-to-be-reported quarter.
This apart, sluggishness in some of Danaher’s key end markets, including Latin America and some European regions, are likely to impact growth. A significant portion of its revenues is derived from regions outside the U.S., which makes it vulnerable to currency fluctuations. Over the past few quarters, Danaher has been suffering from strengthening of both the U.S. dollar and the Japanese yen versus other currencies.
Also, the company has been witnessing relatively smaller organic growth over the past few quarters. We believe Danaher's Life Science portfolio lacks a significant upstream product offering, which has been restricting growth. A decelerating organic growth is likely to affect the company’s overall top-line performance for the second quarter.
Despite these negatives, Danaher’s acquired businesses, namely Pall and Cepheid, are expected to act as key growth drivers for the quarter to be reported. Also, the company’s robust operating culture, DBS, is likely to act as a catalyst. Historically, DBS has contributed to meaningful core revenue growth, adjusted earnings per share improvement and cash flow generation.
Furthermore, positive industry trends like new regulations from the Chinese Food and Drug Administration are expected to act as tailwinds, fueling top-line increase for the second quarter. Also, market traction of the recently launched products, including SMARTmatic handpiece campaign, KaVo OP 3D Pro panoramic X-Ray imaging system and CM130 coring monitoring system, are expected to stoke growth.
Earnings Whispers
Our proven model does not conclusively show that Danaher will beat earnings estimates in this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Earnings ESP for the company is currently 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 97 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Danaher Corporation Price and EPS Surprise
Danaher Corporation price-eps-surprise | Danaher Corporation Quote
Zacks Rank: Danaher has a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Broadcom Limited (AVGO - Free Report) has an Earnings ESP of +1.71% and sports a Zacks Rank #1. The company is expected to release fiscal third-quarter 2017 results on Sep 7. You can see the complete list of today’s Zacks #1 Rank stocks here.
3M Company (MMM - Free Report) has an Earnings ESP of +1.16% and holds a Zacks Rank #2. The company will release second-quarter 2017 earnings on Jul 25.
United Technologies Corporation has an Earnings ESP of +2.26% and carries a Zacks Rank #3. The company will report second-quarter 2017 results on Jul 25.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>